FDA Approves Arcutis ’ Zoryve (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE)— Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news